Press Release
Radiadyne worked closely with HaA to develop an advanced fiber optic dosimeter. After eight years and millions of dollars invested in research and development, OARtrac is the first of its kind radiation dose monitoring platform providing gold standard accuracy without correction factors, real-time pinpoint measurement, and dedicated intracavitary delivery devices to measure where it counts.
The OARtrac monitors multiple cancer treatment modalities within the same treatment center, as well as reduces overall treatment costs related to routine patient dose monitoring through a reusable dosimeter. The OARtrac system provides dose data for the radiation oncologist to decipher and use to adjust a patient’s treatment plan accordingly, therefore providing true adaptive radiotherapy for personalized cancer treatment.
Eric Hyman, HaA’s VP of Engineering, was heavily involved with the overall product development, engineering and manufacturing process of the OARtrac, receiving a 2018 MedTech Engineering Breakthrough Award.
The HaA team worked on the fiber optic sensor cable, central processing device, and delivery devices including two balloon catheters. All parts of the design and development process were employed including industrial design, engineering, optics, manufacturer sourcing, packaging design, sterilization, branding, cart design, and quality / regulatory documentation.
Radiadyne was acquired by Angiodynamics in 2018 as they looked to add disruptive, patient-focused technologies to their oncology portfolio.
Companies Mentioned
Business Categories Mentioned
